Select Topic:
Browse by Series:

Nivolumab and Ipilimumab in mRCC

Insights From: Thomas E. Hutson, DO, PharmD, Baylor University Medical Center; Chung-Han Lee, MD, PhD, Memorial Sloan Kettering Cancer Center; Nizar M. Tannir, MD, FACP, The University of Texas MD Anderson Cancer Center
Published: Thursday, Aug 16, 2018



Transcript: 

Chung-Han Lee, MD, PhD: Ipilimumab is an anti-CTLA4 agent. While nivolumab is an anti–PD-1 agent, both of these checkpoint inhibitors work at different places within the immune system in activation. Anti-CTLA4 is an earlier event, while PD-1 really looks at immune exhaustion. Therefore, there is some preclinical rationale for synergism between them. As a result, these 2, in combination, will likely enhance each other’s effects beyond what is seen with single-agent PD-1 inhibition.

CheckMate 214 was a randomized phase III clinical trial of the combination of ipilimumab plus nivolumab versus sunitinib in first-line–treated patients. These included patients who were both intermediate- and poor-risk disease, as well as patients with favorable-risk disease. Within the intermediate- and poor-risk population, the outcomes were superior in comparison to Sutent (sunitinib)—from an objective response standpoint, a progression-free survival standpoint, and an overall survival standpoint. What was very interesting about that trial was that there also seemed to be some stratification between the intermediate- or poor-risk group versus the favorable-risk population. In the favorable-risk population, we actually saw the reverse effect, in which patients who got single-agent sunitinib seemed to do better than with the combination checkpoint inhibitor regimen.

Transcript Edited for Clarity
Slider Left
Slider Right


Transcript: 

Chung-Han Lee, MD, PhD: Ipilimumab is an anti-CTLA4 agent. While nivolumab is an anti–PD-1 agent, both of these checkpoint inhibitors work at different places within the immune system in activation. Anti-CTLA4 is an earlier event, while PD-1 really looks at immune exhaustion. Therefore, there is some preclinical rationale for synergism between them. As a result, these 2, in combination, will likely enhance each other’s effects beyond what is seen with single-agent PD-1 inhibition.

CheckMate 214 was a randomized phase III clinical trial of the combination of ipilimumab plus nivolumab versus sunitinib in first-line–treated patients. These included patients who were both intermediate- and poor-risk disease, as well as patients with favorable-risk disease. Within the intermediate- and poor-risk population, the outcomes were superior in comparison to Sutent (sunitinib)—from an objective response standpoint, a progression-free survival standpoint, and an overall survival standpoint. What was very interesting about that trial was that there also seemed to be some stratification between the intermediate- or poor-risk group versus the favorable-risk population. In the favorable-risk population, we actually saw the reverse effect, in which patients who got single-agent sunitinib seemed to do better than with the combination checkpoint inhibitor regimen.

Transcript Edited for Clarity
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x